Galapagos NV (NASDAQ:GLPG) Receives $30.75 Consensus Target Price from Analysts

Galapagos NV (NASDAQ:GLPG) has received an average recommendation of “Reduce” from the eight research firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $30.75.

A number of analysts recently weighed in on the stock. Royal Bank of Canada decreased their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating for the company in a research report on Friday, November 1st. Kepler Capital Markets cut shares of Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th. Finally, TD Cowen cut shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th.

Galapagos Price Performance

Shares of NASDAQ GLPG opened at $23.77 on Monday. Galapagos has a 52-week low of $23.57 and a 52-week high of $40.34. The firm has a fifty day moving average of $27.06 and a 200-day moving average of $27.49.

Hedge Funds Weigh In On Galapagos

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in Galapagos in the 2nd quarter valued at about $456,000. GAMMA Investing LLC boosted its position in Galapagos by 77.4% in the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 974 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in Galapagos in the 3rd quarter valued at about $1,077,000. Signaturefd LLC boosted its position in Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 2,541 shares during the last quarter. Finally, Headlands Technologies LLC boosted its position in Galapagos by 56.7% in the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 446 shares during the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.